Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab.

Like 0 Comment
Atopic dermatitis (AD) is a chronic, multifactorial, inflammatory skin disease which can have a negative impact on the quality of life (QoL). The moderate-to-severe forms frequently require systemic treatment. Dupilumab is a human monoclonal antibody directed against the alpha subunit of the IL-4 receptor. It has been the first biologic drug that approved for the treatment of moderate to severe AD.

Click here to read the full article @ Clinical and experimental dermatology
Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
1308 Contributions
0 Following

No comments yet.